Publication Author: Zeliadt_Steven

• Disenrollment from Medicaid after recent cancer diagnosis.

  Ramsey SD, Zeliadt SB, Richardson LC, Pollack L, Linden H, Blough DK, Anderson N. Disenrollment from Medicaid after recent cancer diagnosis. Med Care. 2008 Jan;46(1):49-57.

  rakerr2

  January 1, 2008

• Computer-assisted mammography feedback program (CAMFP) an electronic tool for continuing medical education.

  Urban N, Longton GM, Crowe AD, Drucker MJ, Lehman CD, Peacock S, Lowe KA, Zeliadt SB, Gaul MA. Computer-assisted mammography feedback program (CAMFP) an electronic tool for continuing medical education. Acad Radiol. 2007 Sep;14(9):1036-42.

  rakerr2

  September 1, 2007

• On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer.

  Ramsey SD, Zeliadt SB, Hall IJ, Ekwueme DU, Penson DF. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. J Urol. 2007 Jun;177(6):1992-9. Review.

  rakerr2

  June 1, 2007

• Pharmacoeconomics of available treatment options for metastatic prostate cancer.

  Zeliadt SB, Penson DF. Pharmacoeconomics of available treatment options for metastatic prostate cancer. Pharmacoeconomics. 2007;25(4):309-27. Review.

  rakerr2

  April 1, 2007

• Trends in treatment costs for localized prostate cancer: the healthy screenee effect.

  Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care. 2007 Feb;45(2):154-9.

  rakerr2

  February 1, 2007

• Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer.

  Zeliadt SB, Potosky AL, Penson DF, Etzioni R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66

  rakerr2

  October 1, 2006

• Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer.

  Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer. 2006 May 1;106(9):1865-74.

  rakerr2

  May 1, 2006

• Estimated impact of the prostate cancer prevention trial on population mortality.

  Zeliadt SB, Etzioni R, Kristal AR. Estimated impact of the prostate cancer prevention trial on population mortality. Cancer. 2005 Oct 1;104(7):1556-7; author reply 1557.

  rakerr2

  October 1, 2005

• Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.

  Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med. 2005 Aug;118(8):850-7.

  rakerr2

  August 1, 2005

• An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.

  Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol. 2004 Dec 1;160(11

  rakerr2

  December 1, 2004